Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
Author:
Funder
F. Hoffmann-La Roche Ltd
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/20/11/1842/473906/mdp233.pdf
Reference17 articles.
1. Role of vascular endothelial growth factor in regulation of physiological angiogenesis;Ferrara;Am J Physiol Cell Physiol,2001
2. The biology of VEGF and its receptors;Ferrara;Nat Med,2003
3. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy;Jain;Nat Med,2001
4. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer;Kabbinavar;J Clin Oncol,2005
5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
Cited by 466 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Ugly: Metastatic Colon Cancer—Surgical Options;Clinics in Colon and Rectal Surgery;2024-06-18
2. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial;Signal Transduction and Targeted Therapy;2024-04-03
3. A narrative review on therapeutic potential of naringenin in colorectal cancer: Focusing on molecular and biochemical processes;Cell Biochemistry and Function;2024-04
4. The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco;Cureus;2024-03-22
5. Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives;Cancers;2024-02-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3